Skip to main content
. 2009 May 12;11(2):353–363. doi: 10.1208/s12248-009-9111-6

Fig. 1.

Fig. 1

Valacyclovir simulations using experimental distributions of PepT1. Oral doses of valacyclovir (100 to 1,000 mg) administered to volunteers at risk for developing Herpes simplex virus (HSV) (39). a Using the Englund distribution of PepT1 (23). b Using the Herrera–Ruiz distribution of Pept1